Join this session to explore how obesity trials and treatment paradigms must evolve with GLP-1 agonists as the new backbone therapy. Experts will debate optimal approaches for testing combinations and sequencing therapies, addressing critical questions about trial design, phenotypic targeting, and weight rebound mitigation.

• Determining patient-centric cardiometabolic endpoints to extend beyond weight loss while satisfying payer demands
• Combining dual GLP-1 and myostatin inhibitors to reduce muscle mass loss for greater metabolic health and explore composite endpoints that reflect real-world patient priorities to lower trial dropout rates
• Exploring sequential therapy protocols to reduce GI side effects for improved long-term adherence
• Reducing weight cycling by shifting focus from acute weight loss to sustained metabolic outcomes